153885-60-0

Basic information

• Product Name: Hydrazinecarboxamide, N-(4-fluorophenyl)-
• CAS NO: 153885-60-0
• Molecular Formula: C7H8FN3O
• Molecular Weight: 169.158
• Mol File: 153885-60-0.mol
• Article Data: 22

Chemical Properties

• CAS DataBase Reference: Hydrazinecarboxamide, N-(4-fluorophenyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Hydrazinecarboxamide, N-(4-fluorophenyl)-(153885-60-0)
• EPA Substance Registry System: Hydrazinecarboxamide, N-(4-fluorophenyl)-(153885-60-0)

Safety Data

• Hazardous Substances Data: 153885-60-0(Hazardous Substances Data)

Upstream product

• 459-25-6 N-(4-fluorophenyl)formamide 
• 1195-45-5 para-fluorophenyl isocyanate 
• 457-77-2 ethyl 4-fluorophenylcarbamate 
• 659-30-3 1-(4-fluorophenyl)urea 
• 65141-04-0 phenyl N-(4-fluorophenyl)carbamate 
• 371-40-4 4-fluoroaniline 

Downstream Products

• 1198272-49-9 1-(2-ethyl-4-oxo-4H-quinazolin-3-yl)-3-(4-fluoro-phenyl)-urea 
• 1198272-38-6 1-(4-fluoro-phenyl)-3-(4-oxo-2-phenyl-4H-quinazolin-3-yl)-urea 

Relevant articles and documents

Design and synthesis of new 2,5-disubstituted-1,3,4-oxadiazole analogues as anticancer agents

In continuance of our search for new anticancer agents, we report herein the design, synthesis, and anticancer evaluation of oxadiazole analogues. Two series (4a-h and 4i-q) of new oxadiazole analogues were designed based on heterocyclic (1,3,4-oxadiazole

Synthesis, In-vitro evaluation and molecular docking studies of oxoindolin phenylhydrazine carboxamides as potent and selective inhibitors of ectonucleoside triphosphate diphosphohydrolase (NTPDase)

Members of the ectonucleoside triphosphate diphosphohydrolases (NTPDases) constitute the major family of enzymes responsible for the maintenance of extracellular levels of nucleotides and nucleosides by catalyzing the hydrolysis of nucleoside triphosphate

Design and synthesis of novel N-(4-(Pyridin-2-yloxy)benzylidene)-4-[4-(substituted)phenyl]semicarbazides as potential anticonvulsant agents

A new series of N-(4-(pyridin-2-yloxy)benzylidene)-4-[4-(substituted)phenyl]semicarbazides (PSSD1-8) were designed and synthesized keeping in view the structural requirement of pharmacophore and evaluated for their possible anticonvulsant activity. All the derivatives were synthesized by the given scheme and reaction process was monitored by thin layer chromatography. The structure of synthesized derivatives was confirmed by FT-IR, 1H NMR, mass spectroscopy and elemental analysis. The anticonvulsant activity was established after intraperitoneal administration in MES and scMET seizure models. The most active compound of the series was 1-(4-(pyridin-2-yloxy)-benzylidene)-4-p-tolylsemicarbazide (PSSD5). A molecular docking study was carried out in order to assess the interaction and binding modes with target receptor/enzyme. Titled compounds were found to strongly bind to human gamma-aminobutyric acid receptor (GABAAR-β3). A computational study was also carried to predict the pharmacokinetic properties of the synthesized compounds.